Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Open accessThe DOI matches its Crossref record; 1,028 of the 1,028 references it cites were found in a registry or an index.
Abstract
Cancer remains a significant risk to human health. Nanomedicine is a new multidisciplinary field that is garnering a lot of interest and investigation. Nanomedicine shows great potential for cancer diagnosis and treatment. Specifically engineered nanoparticles can be employed as contrast agents in cancer diagnostics to enable high sensitivity and high-resolution tumor detection by imaging examinations. Novel approaches for tumor labeling and detection are also made possible by the use of nanoprobes and nanobiosensors. The achievement of targeted medication delivery in cancer therapy can be accomplished through the rational design and manufacture of nanodrug carriers. Nanoparticles have the capability to effectively transport medications or gene fragments to tumor tissues via passive or active targeting processes, thus enhancing treatment outcomes while minimizing harm to healthy tissues. Simultaneously, nanoparticles can be employed in the context of radiation sensitization and photothermal therapy to enhance the therapeutic efficacy of malignant tumors. This review presents a literature overview and summary of how nanotechnology is used in the diagnosis and treatment of malignant tumors. According to oncological diseases originating from different systems of the body and combining the pathophysiological features of cancers at different sites, we review the most recent developments in nanotechnology applications. Finally, we briefly discuss the prospects and challenges of nanotechnology in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 1,001–1,028 of 1,028
Yu, T., Tong, L., Ao, Y., Zhang, G., Liu, Y., & Zhang, H. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1775723 · Cited by 20
Skeletal health in patients with differentiated thyroid carcinoma
Cellini, M., Rotondi, M., Tanda, M. L., Piantanida, E., Chiovato, L., Beck-Peccoz, P., Lania, A. G., & Mazziotti, G. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01359-6 · Cited by 20
Extracellular vesicles as a liquid biopsy for melanoma: Are we there yet?
Medhin, L. B., Beasley, A. B., Warburton, L., Amanuel, B., & Gray, E. S. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.01.008 · Cited by 20
CAR-T cells for cancer immunotherapy
Xie, Y., Li, X., Wu, J., Zeng, H., Boucetta, H., Wang, B., Yang, P., & He, W. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108202 · Cited by 20
Self-citationZhang, Y., Wang, R., Li, W., Huang, G., Zhu, J., Cheng, J., & He, D. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb01874c · Cited by 19
Melanoma: How and when to consider clinical diagnostic technologies
Skudalski, L., Waldman, R. A., Kerr, P. E., & Grant-Kels, J. M. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.06.901 · Cited by 19
Fokas, E., Glynne‐Jones, R., Fleischmann, M., Piso, P., Tselis, N., Ghadimi, M. B., Hofheinz, R., & Rödel, C. M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102490 · Cited by 19
Lee, J., Appelmann, I., Miething, C., Shultz, T. O., Ruderman, D., Kim, D., Mallick, P., Lowe, S. W., & Wang, S. X. (2018) · Theranostics · doi:10.7150/thno.20706 · Cited by 18
Yan, S., Zhao, W., Wang, B., & Zhang, L. (2018) · Medicine · doi:10.1097/md.0000000000011364 · Cited by 17
Self-citationMajd, N., & de Groot, J. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1621840 · Cited by 17
Bacha, D. S., Rahme, M., Al‐Shaar, L., Baddoura, R., Halaby, G., Singh, R. J., Mahfoud, Z. R., Habib, R., Arabi, A., & Fuleihan, G. E. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab296 · Cited by 17
Pellacani, G., & Argenziano, G. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18197 · Cited by 17
Choi, J.-W., Kim, H., Nam, K., Na, Y., Yun, C., & Kim, S. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.068 · Cited by 16
Wang, B., Su, A., Xing, T., Luo, H., Zhao, W., & Zhu, J. (2018) · Medicine · doi:10.1097/md.0000000000011778 · Cited by 16
Self-citationSelf-Therapeutic Cobalt Hydroxide Nanosheets (Co(OH)2 NS) for Ovarian Cancer Therapy
Adeel, M., Parisi, S., Mauceri, M., Asif, K., Bartoletti, M., Puglisi, F., Caligiuri, I., Rahman, M. M., Canzonieri, V., & Rizzolio, F. (2021) · ACS Omega · doi:10.1021/acsomega.1c03010 · Cited by 16
Dykas, M. M., Poddar, K., Yoong, S. L., Viswanathan, V., Mathew, S., PATRA, A., SAHA, S., Pastorin, G., & Venkatesan, T. (2017) · Journal of Microscopy · doi:10.1111/jmi.12604 · Cited by 15
Gadolinium-Bisphosphonate Nanoparticle-Based Low-Dose Radioimmunotherapy for Osteosarcoma
Zhang, S., Wu, Y., Yu, J., Ma, C., Wang, Y., Wang, Y., Li, L., & Zhang, L. W. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00880 · Cited by 15
Delivery siRNA with a novel gene vector for glioma therapy by targeting Gli1
Zhou, P., Cao, Y. Z., Liu, X., Yu, T., Xu, Q., You, C., Gao, X., & Wei, Y. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s164364 · Cited by 14
Self-citationThyroid cancer MR molecular imaging via SHP2-targeted nanoparticles
Hu, Z., Qin, J., Li, T., & Guo, J. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s201358 · Cited by 14
Wang, C., Zhang, R., Tan, J., Meng, Z., Zhang, Y., Li, N., Wang, H., Chang, J. K., & Wang, R. (2020) · Oncology Reports · doi:10.3892/or.2020.7537 · Cited by 14
Self-citationRecent progress in nanomedicines for imaging and therapy of brain tumors
Hasan, I., Roy, S., Guo, B., Du, S., Tao, W., & Chang, C. (2022) · Biomaterials Science · doi:10.1039/d2bm01572b · Cited by 14
Microfluidic Reconstitution of Tumor Microenvironment for Nanomedical Applications
Oh, H. J., Kim, J., Kim, H., Choi, N., & Chung, S. H. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002122 · Cited by 13
Modular design of Bi-specific nanoplatform engaged in malignant lymphoma immunotherapy
Bai, C., Hu, P., Zhang, W., Song, L., Liu, D., Chen, Y., Ma, M., Gu, N., & Zhang, Y. (2020) · Nanoscale · doi:10.1039/d0nr04450d · Cited by 12
Nanoparticle-Based Techniques for Bladder Cancer Imaging: A Review
Boschi, F., & Malatesta, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043812 · Cited by 11
Tassinari, D., Cherubini, C., Roudnas, B., et al. (2018) · Reviews on Recent Clinical Trials · doi:10.2174/1574887113666180404120540 · Cited by 10
Management of cutaneous melanoma in Australia: a narrative review
Bhave, P., Wong, J., McInerney-Leo, A. M., Cust, A. E., Lawn, C., Janda, M., & Mar, V. (2023) · The Medical Journal of Australia · doi:10.5694/mja2.51910 · Cited by 10
Fanfone, D., Despretz, N., Stanicki, D., Rubio‐Magnieto, J., Fossepré, M., Surin, M., Rorive, S., Salmon, I. J., Elst, L. V., Laurent, S., et al. (2017) · Medical Oncology · doi:10.1007/s12032-017-1042-y · Cited by 6
Structure-based classification of EGFR mutations informs inhibitor selection for lung cancer therapy
Yenerall, P. M., Kittler, R., & Minna, J. D. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.012 · Cited by 6
Cited by
Exploring and bypassing resistance to targeted therapies in colorectal cancer
Favier, S., Xiong, W., Chalabi-Dchar, M., Chettab, K., Piercey, O., Wu, T., Fenouil, T., Albaret, M.-A., Jordheim, L. P., Diaz, J.-J., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118741 · Cited by 12
Tao, J., Ning, W., Lu, W., Wang, R., Zhou, H., Zhang, H., Xu, J., Wang, S., Teng, Z., & Wang, L. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.01.058 · Cited by 10
Self-citation
Metadata
- Authors
- Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-08-12
- Volume
- 9
- Issue
- 1
- Pages
- 200-200
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4401497204
- Cited by
- 558
- References
- 1,028
- FWCI
- 58.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.